Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Receives Average Rating of “Buy” from Analysts

Shares of Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) have earned an average rating of “Buy” from the ten ratings firms that are covering the firm, MarketBeat reports. Eight analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $46.4286.

A number of brokerages recently commented on AAPG. BTIG Research reiterated a “buy” rating and set a $48.00 price objective on shares of Ascentage Pharma Group International in a research report on Monday, April 13th. Raymond James Financial reissued a “buy” rating on shares of Ascentage Pharma Group International in a research note on Wednesday. B. Riley Financial began coverage on Ascentage Pharma Group International in a research note on Wednesday. They set a “buy” rating and a $45.00 target price for the company. Deutsche Bank Aktiengesellschaft began coverage on Ascentage Pharma Group International in a research note on Friday, April 24th. They set a “buy” rating and a $40.00 target price for the company. Finally, China Intl Cap raised Ascentage Pharma Group International to a “strong-buy” rating in a research note on Monday, April 6th.

Institutional Investors Weigh In On Ascentage Pharma Group International

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Citadel Advisors LLC acquired a new stake in Ascentage Pharma Group International during the third quarter worth $383,000. XY Capital Ltd increased its stake in Ascentage Pharma Group International by 224.2% during the third quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock worth $707,000 after acquiring an additional 12,530 shares during the last quarter. UBS Group AG increased its stake in Ascentage Pharma Group International by 149.4% during the third quarter. UBS Group AG now owns 18,345 shares of the company’s stock worth $716,000 after acquiring an additional 10,988 shares during the last quarter. Finally, Hsbc Holdings PLC acquired a new stake in shares of Ascentage Pharma Group International in the second quarter valued at $391,000.

Ascentage Pharma Group International Trading Up 2.9%

NASDAQ AAPG opened at $17.60 on Friday. The stock’s 50 day simple moving average is $22.10 and its 200-day simple moving average is $24.75. Ascentage Pharma Group International has a 1-year low of $16.92 and a 1-year high of $48.45. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.77 and a current ratio of 1.79.

Ascentage Pharma Group International (NASDAQ:AAPG) last released its earnings results on Wednesday, March 25th. The company reported ($0.52) earnings per share for the quarter. The firm had revenue of $24.72 million during the quarter. Research analysts anticipate that Ascentage Pharma Group International will post -0.96 earnings per share for the current year.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.